The cost effectiveness of 123I-FP-CIT SPECT imaging in patients with an uncertain clinical diagnosis of parkinsonism

  • Koen Van Laere
  • Ludwig Everaert
  • Lieven Annemans
  • Michel Gonce
  • Wim Vandenberghe
  • Thierry Vander Borght
Original Article



123I-N-ω-fluoropropyl-2-β-carboxymethoxy-3β-(4-iodophenyl)nortropane (123I-FP-CIT) Single-photon emission computed tomography (SPECT) has been suggested to be a useful diagnostic adjunct in patients with clinically uncertain parkinsonism. We developed a pharmaco-economic (PE) model, evaluating the cost effectiveness of adding 123I-FP-CIT SPECT to the diagnostic workup. As the model was developed before application of the diagnostic technique in real practice, a predictive validity assessment was performed based on data from a large nationwide patient registry in these patients.


A PE model, using a Markov state transition model, was created, based on literature-derived and clinical expert panel data. Effects were expressed as adequately treated years (ATY). Key input data were compared to the real-life patterns in a nationwide multi-centre clinical setting, based on a complete national registry of 1,701 consecutive patients. The change in initial diagnosis and alteration of management of the patient after SPECT were registered.


In the PE model, it was calculated that management would change in 48.5% of patients by SPECT and that, over a 5-year period, 1.2 ATYs could be gained at a yearly additional cost of €72. From the studied 1,701 patients, nigrostriatal degeneration was observed in 59.8%, the initial diagnosis was changed in 51.5%, management was altered in 49%, and cost effectiveness was increased to €358 per ATY.


Good correspondence between assumed and observed changes in patient management was found, indicating that 123I-FP-CIT SPECT is influential in diagnosis and management of patients with uncertain clinical diagnosis of parkinsonism. This can be achieved at a marginal added cost to the health insurance and leads to a significant gain in ATY.


123I-FP-CIT Dopamine transporter Clinical impact Pharmaco-economic modelling 


  1. 1.
    Booij J, Speelman JD, Horstink MW, Wolters EC. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med 2001;28:266–72.PubMedCrossRefGoogle Scholar
  2. 2.
    Lokkegaard A, Werdelin LM, Friberg L. Clinical impact of diagnostic SPET investigations with a dopamine re-uptake ligand. Eur J Nucl Med Mol Imaging 2002;29:1623–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Eerola J, Tienari PJ, Kaakkola S, Nikkinen P, Launes J. How useful is [123I]beta-CIT SPECT in clinical practice? J Neurol Neurosurg Psychiatry 2005;76:1211–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Hesse S, Oehlwein C, Barthel H, et al. Possible impact of dopamine SPECT on decision-making for drug treatment in Parkinsonian syndrome. J Neural Transm 2006;113:1177–90.PubMedCrossRefGoogle Scholar
  5. 5.
    Benamer TS, Patterson J, Grosset DG, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 2000;15:503–10.PubMedCrossRefGoogle Scholar
  6. 6.
    Catafau AM, Tolosa E. Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. Mov Disord 2004;19:1175–82.PubMedCrossRefGoogle Scholar
  7. 7.
    Ravina B, Eidelberg D, Ahlskog JE, et al. The role of radiotracer imaging in Parkinson disease. Neurology 2005;64:208–15.PubMedGoogle Scholar
  8. 8.
    Dodel RC, Hoffken H, Moller JC, et al. Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinson’s disease: a decision-analytic approach. Mov Disord 2003;7(18 Suppl):S52–62.CrossRefGoogle Scholar
  9. 9.
    Meara J, Bhowmick BK, Hobson P. Accuracy of diagnosis in patients with presumed Parkinson’s disease. Age Ageing 1999;28:99–102.PubMedCrossRefGoogle Scholar
  10. 10.
    Andersen PK, Keiding N. Multi-state models for event history analysis. Stat Methods Med Res 2002;11:91–115.PubMedCrossRefGoogle Scholar
  11. 11.
    Cooper K, Brailsford SC, Davies R, Raftery J. A review of health care models for coronary heart disease interventions. Health Care Manag Sci 2006;9:311–24.PubMedCrossRefGoogle Scholar
  12. 12.
    Koch W, Hamann C, Radau PE, Tatsch K. Does combined imaging of the pre- and postsynaptic dopaminergic system increase the diagnostic accuracy in the differential diagnosis of parkinsonism? Eur J Nucl Med Mol Imaging 2007;34:1265–73.PubMedCrossRefGoogle Scholar
  13. 13.
    Tanner CM, Hubble JP, Chan P. Epidemiology and genetics of Parkinson’s disease. In: Watts RL, Koller WC, editors. Movement disorders. New York: McGraw-Hill; 1997. p. 137–52.Google Scholar
  14. 14.
    Seibyl JP, Marek K, Sheff K, et al. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson’s patients. J Nucl Med 1998;39:1500–8.PubMedGoogle Scholar
  15. 15.
    Van Laere K, De Ceuninck L, Dom R, et al. Dopamine transporter SPECT using fast kinetic ligands: 123I-FP-beta-CIT versus 99mTc-TRODAT-1. Eur J Nucl Med Mol Imaging 2004;31:1119–27.PubMedCrossRefGoogle Scholar
  16. 16.
    Acton PD, Newberg A, Plossl K, Mozley PD. Comparison of region-of-interest analysis and human observers in the diagnosis of Parkinson’s disease using [99mTc]TRODAT-1 and SPECT. Phys Med Biol 2006;51:575–85.PubMedCrossRefGoogle Scholar
  17. 17.
    Chou KL, Hurtig HI, Stern MB, et al. Diagnostic accuracy of [99mTc]TRODAT-1 SPECT imaging in early Parkinson’s disease. Parkinsonism Relat Disord 2004;10:375–9.PubMedCrossRefGoogle Scholar
  18. 18.
    McKeith I, O’Brien J, Walker Z, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 2007;6:305–13.PubMedCrossRefGoogle Scholar
  19. 19.
    Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism—a prospective study. Can J Neurol Sci 1991;18:275–8.PubMedGoogle Scholar
  20. 20.
    Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181–4.PubMedCrossRefGoogle Scholar
  21. 21.
    Jankovic J. Essential tremor: clinical characteristics. Neurology 2000;54:S21–5.PubMedGoogle Scholar
  22. 22.
    Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000;342:1484–91.PubMedCrossRefGoogle Scholar
  23. 23.
    Beyer MK, Herlofson K, Arsland D, Larsen JP. Causes of death in a community-based study of Parkinson’s disease. Acta Neurol Scand 2001;103:7–11.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Koen Van Laere
    • 1
  • Ludwig Everaert
    • 2
  • Lieven Annemans
    • 3
  • Michel Gonce
    • 4
  • Wim Vandenberghe
    • 5
  • Thierry Vander Borght
    • 6
  1. 1.Division of Nuclear MedicineUniversity Hospital Leuven GasthuisbergLeuvenBelgium
  2. 2.Medical and Pharmaceutical InformationZemstBelgium
  3. 3.Department of Public HealthGhent UniversityGhentBelgium
  4. 4.Department of NeurologyCHU CitadelleLiègeBelgium
  5. 5.Department of NeurologyUniversity Hospital LeuvenLeuvenBelgium
  6. 6.Division of Nuclear Medicine, Mont-Godinne Medical CenterUniversité Catholique de LouvainYvoirBelgium

Personalised recommendations